Foundayo (Orforglipron) Explained: The New Daily GLP-1 Pill with No Food Restrictions

Foundayo became the second FDA-approved oral GLP-1 for weight loss when the FDA approved it on April 1, 2026 — just four months after oral Wegovy. But Foundayo isn't just "another oral GLP-1." It's a fundamentally different molecule with a headline advantage: no food or water restrictions, any time of day.

What Makes Foundayo Different

Foundayo's active ingredient is orforglipron — a small molecule GLP-1 receptor agonist. Unlike semaglutide (a peptide), orforglipron is chemically stable in stomach acid. No SNAC protection needed, no fasting window, no water restrictions. Take it whenever you want, however you want.

The FDA approved Foundayo under the Commissioner's National Priority Voucher program — the fastest new molecular entity approval since 2002. It was approved just 50 days after filing, nearly 10 months ahead of its original review deadline.

Dosing

Foundayo uses a dose escalation ladder: 0.8mg → 2.5mg → 5.5mg → 9mg → 14.5mg → 17.2mg (maintenance). Patients titrate up over several weeks to reach the maintenance dose, which helps minimize GI side effects during the adjustment period.

How to Get Foundayo

Foundayo is available through LillyDirect (Eli Lilly's direct-to-patient platform) and retail pharmacies nationwide. Through Sesame Care, you can get a clinician visit and prescription for Foundayo or oral Wegovy — brand-name, FDA-approved medications only.

Foundayo vs Oral Wegovy

Oral Wegovy delivers more weight loss on average, but Foundayo's convenience advantage is real. For many patients, the ability to take medication without timing restrictions outweighs a few percentage points of additional weight loss.